Classifying Structural Joint Damage in Rheumatoid Arthritis as Progressive or Nonprogressive Using a Composite Definition of Joint Radiographic Change: A Preliminary Proposal

Arthritis and Rheumatism

Volumn 50, Issue 4, 2004, Pages 1083-1096

  Paulus, Harold E ^a,c   Oh, MyungShin ^a   Sharp, John T ^b   Gold, Richard H ^a   Wong, Weng Kee ^a   Park, Grace S ^a   Bulpitt, Ken J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ARTHROGRAPHY; CONTROLLED CLINICAL TRIALS; DISEASE PROGRESSION; FOOT JOINTS; HUMANS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; WRIST JOINT;

EID: 1842683004     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20270     Document Type: Article

References (46)

1. Paulus HE, van der Heijde D, Bulpitt KJ, Gold RH. Monitoring radiographic changes in early rheumatoid arthritis. J Rheumatol 1996;23:801-5.
2. Hulsmans HM, Jacobs JW, van der Heijde DM, van Alboda-Kuipers GA, Schenk Y, Bijlsma JW. The course of radiologic damage during the first six years of rheumatoid arthritis. Arthritis Rheum 2000;43:1927-40.
3. Scott DL, Pugner K, Kaarela K, Doyle DV, Woolf A, Holmes J, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology 2000;39:122-32.
4. Wolfe F, Flowers N, Anderson J. Radiographic progression predicts substantial income loss and work disability in rheumatoid arthritis [abstract]. Arthritis Rheum 2000;43 Suppl 9:S403.
5. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 1977;18:481-91.
6. Edmonds JP, Scott DL, Furst DE, Brooks P, Paulus HE. Antirheumatic drugs: a proposed new classification. Arthritis Rheum 1993;36:336-40.
7. United States Department of Health and Human Services, Food and Drug Administration. Guidance for industry: Clinical development programs for drugs, devices and biological products for the treatment of rheumatoid arthritis. URL: www.fda.gov.
8. Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 2000;43:495-505.
9. Kirwan JR, and the Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995;333:142-6.
10. Wassenburg S, Rau R, Zeidler H. Low dose prednisolone retards radiographically detectable destruction in early rheumatoid arthritis [abstract]. Arthritis Rheum 1999;42 Suppl 9:S243.
11. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domeljian Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
12. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
13. Bathon JM, Martin RW, Fleischmann RM, Tessar JR, Schiff MH, Keystone E, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
14. Joint Committee of the Medical Research Council and Nuffield Foundation. Clinical trials of cortisone, ACTH and other therapeutic measures in chronic rheumatic diseases: a comparison of prednisolone with aspirin and other analgesics in the treatment of rheumatoid arthritis. Ann Rheum Dis 1960;19:331-7.
15. Van Everdingen AA, Jacobs JW, Siewertsz van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 2002;136:1-12.
16. Pasero G, Priolo F, Marubini E, Fantini F, Ferracioli G, Magaro M, et al. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. J Rheumatol 1997;24:2113-8.
17. Førre O. Radiologic evidence of disease modification in rheumatoid arthritis patients treatment with cyclosporine: results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Arthritis Rheum 1994;37:1506-12.
18. Jeurissen ME, Boerbooms AM, van der Putte LB, Doesburg WH, Lemmens AM. Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis: a randomized double-blind study. Ann Intern Med 1991;114:999-1004.
19. Weinblatt ME, Polisson R, Blotner SD, Sosman JL, Aliabadi P, Baker N, et al. The effects of drug therapy on radiographic progression of rheumatoid arthritis: results of a 36-week randomized trial comparing methotrexate and auranofin. Arthritis Rheum 1993;36:613-9.
20. Alarcon GS, Lopez-Mendez A, Walter J, Boerbooms AM, Russell AS, Furst DE, et al. Radiographic evidence of disease progression in methotrexate treated and nonmethotrexate disease modifying antirheumatic drug treated rheumatoid arthritis patients: a meta-analysis. J Rheumatol 1992;19:1868-73.
21. Van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, van de Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;1:1036-8.
22. Hannonen P, Möttönen T, Hakola M, Oka M. Sulfasalazine in early rheumatoid arthritis. Arthritis Rheum 1993;36:1501-9.
23. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
24. Landewé RB, Boers M, Verhoeven AC, Westhovens R, van de Laar M, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56.
25. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine, and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334:1287-91.
26. Möttönen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al, for the FIN-RACo trial group. Comparison of combination therapy with single drug therapy in early rheumatoid arthritis: a randomized trial. Lancet 1999;353:1568-73.
27. Csuka M, Carrera GF, McCarty DJ. Treatment of intractable rheumatoid arthritis with combined cyclophosphamide, azathioprine and hydroxychloroquine: a follow-up study. JAMA 1986;255:2115-9.
28. Keystone E, Kavanaugh A, Sharp J, Hua Y, Teoh L, Fischkoff S, et al. Adalimumab (D2E7), a fully human anti-TNFα monoclonal antibody, inhibits the progression of structural joint damage in patients with active RA despite concomitant methotrexate therapy [abstract]. Arthritis Rheum 2002;46 Suppl 9:S205.
29. Lassere M, Boers M, van der Heijde D, Boonen A, Edmonds J, Saudan A, et al. Smallest detectable difference in radiological progression. J Rheumatol 1999;26:731-9.
30. Sharp JT, Lidsky MD, Collins LC, Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Arthritis Rheum 1971;14:706-20.
31. Sharp JT, Young DY, Bluhm GB, Brook A, Brower AC, Corbett M, et al. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? Arthritis Rheum 1985;28:1326-35.
32. Van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000;27:261-3.
33. Paulus HE, Egger MJ, Ward JR, Williams HJ, for the Cooperative Systematic Studies of Rheumatic Diseases Group. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 1990;33:477-84.
34. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. The American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
35. Arnett FL, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
36. Felson D, Anderson J, Boers M, Bombardier C, Chernoff M, Fried B, et al. American College of Rheumatology core set of disease activity measures for use in rheumatoid arthritis clinical trials. Arthritis Rheum 1993;36:729-40.
37. Van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Arthritis Rheum 1996;39:34-40.
38. Fleiss JL. The design and analysis of clinical experiments. New York: John Wiley & Sons; 1986.
39. Bland D, Altman M. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10.
40. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale (NJ): Erlbaum; 1998.
41. Wells G, Boers M, Shea B, Tugwell P, Westhovens R, Suarez-Almazor M, et al. Sensitivity to change of generic quality of life instruments in rheumatoid arthritis: preliminary findings in the generic health OMERACT study. J Rheumatol 1999;26:217-21.
42. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
43. Van der Heijde D, Boonen A, Boers M, Kostinse P, van der Linden S. Reading radiographs in chronological order, in pairs or as single films, has important implications for the discriminative power of rheumatoid arthritis clinical trials. Rheumatology (Oxford) 1999;38:1213-20.
44. Bruynesteyn K, van der Heijde D, Boers M, Saudan A, Peloso P, Paulus H, et al. Detecting radiological changes in rheumatoid arthritis that are considered important by clinical experts: influence of reading with or without known sequence. J Rheumatol 2002;29:2306-12.
45. Lassere MN, van der Heijde D, Johnson K, Bruynesteyn K, Molenaar E, Boonen A, et al. Robustness and generalizability of smallest detectable difference in radiological progression. J Rheumatol 2001;28:911-3.
46. Bruynesteyn K, van der Heijde D, Boers M, Saudan A, Peloso P, Paulus H, et al. Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum 2002;46:913-20.